Pharmaceutical stocks have been under the US FDA cloud. Will 2017 fare better? CNBC-TV18's Latha Venkatesh & Sonia Shenoy asks Arpit Vyas, MD of Dishman Pharmaceuticals & Chemicals, Surajit Pal of Prabhudas Lilladher and Vishal Manchanda of Nirmal Bang Institutional Equities.

Dishman Pharma's Swiss units clear US FDA inspection

Dishman Pharma‘s all global plants, except China, have been cleared by the US FDA, says JR Vyas, CMD of the company.

Exports to US will continue normally post audit: Dishman Pharma

Two minor observations pertaining to a 2014 audit were reported by the US FDA in its recent inspection, says JR Vyas, CMD of Dishman Pharma.

Not received warning from USFDA on Clovis: Dishman Pharma

JR Vyas, CMD, Dishman Pharma in an interview to CNBC-TV18 clarified that the company had not received any warning from US FDA on Clovis issue.

Aim Rs 250 cr sales for Vitamin D biz by FY15 end: Dishman

The pharma company is eyeing capex of around Rs 50-60 crore this fiscal year.

Margins to scale up to 20% by FY15-end: Dishman Pharma

The company is now concentrating on high margins and high value business and expects a sizable improvement by the end of the year.

Dishman Pharma expects earnings to improve in Q3, Q4

In an interview to CNBC-TV18‘s Anuj Singhal and Sonia Shenoy, Arpit Vyas, Managing Director of Dishman Pharma spoke about the latest happenings in the company and the road ahead.

May surpass FY14 rev guidance by 5%: Dishman Pharma

JR Vyas, CMD, Dishman Pharma said the sale of SEZ land is likely to be concluded in the next fiscal.

I-T survey for Rs 42cr land deal; will take action: Dishman

The income tax department's surveyed Dishman Pharma's premises over the weekend for taxation issues in a Rs 42 crore land deal involving Dishman SEZ and Dishman Pharma.

Expect to cut debt by Rs 70-80 cr this year: Dishman Pharma

Arpit Vyas, MD, Dishman Pharma aims at working with EBITDA margins not below USD 25-30 percent and expects to pare down the company debt by Rs 70-80 crore this calendar year.

Dishman Pharma to repay Rs 100cr debt in FY13

Pharma player Dishman Pharma is looking to cut its debt of Rs 100 crore in FY13. JR Vyas, managing director, Dishman Pharma told CNBC-TV18 that the company would be selling its SEZ land to repay debt.

Creapharm buy funded via internal accruals: Dishman Pharma

Dishman Pharmaceuticals and Chemicals' subsidiary Carbogen Amcis AG has acquired Creapharm Parenterals. In an interview to CNBC-TV18, VVS Murthy, chief financial officer of Dishman Pharma says, it is a small R&D formulation development company. The acquisition, he says, is funded trough internal accruals.

FY12 profit to be better than FY11: Dishman Pharma

Dishman's Managing Director JR Vyas expects its key clients Abbott's contribution to grow by 50%. He further expects some more product orders coming in from Abbott in FY13.

Dishman Pharma expects a 15% growth in FY12

In an interview to CNBC-TV18, Dishman Pharma's chief financial officer VVS Murthy said that the change in rupee would not impact the company’s revenues. Murthy projects the company's growth at 15% in FY12.

Dishman Pharma expects 15% consolidated growth, says CFO

In an exclusive interview with CNBC-TV18, VVS Murthy, CFO of Dishman Pharma says that the company has announced a consolidated guidance of 21.5-22% EBITDA margins and is expecting 15% growth on a consolidated level for FY12.

Dishman Pharma eyes 15% topline, bottomline growth in FY12

In an interview with CNBC-TV18, VVS Murthy, CFO, Dishman Pharma said the company is expecting 15% top-line and bottom-line growth in FY12.

Dishman Pharma eyes 15% growth in FY12

VVS Murthy, CFO of Dishman Pharma, in an interview with CNBC-TV18's Latha Venkatesh and Gautam Broker, spoke about the recent report by one of the brokerages Indiabulls Securities, which downgraded the company's stocks and the road ahead.